Trial Profile
Phase 3, Multicenter, Randomized, Double-blind, Placebo and Active Comparator-controlled Study Evaluating the Efficacy and Safety of Guselkumab in the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 Oct 2023
Price :
$35
*
At a glance
- Drugs Guselkumab (Primary) ; Adalimumab
- Indications Plaque psoriasis
- Focus Registrational; Therapeutic Use
- Acronyms VOYAGE 1
- Sponsors Janssen Research & Development; Janssen-Cilag
- 07 Oct 2023 Results of the 5-year post hoc analysis comparing baseline characteristics of patients maintaining a Psoriasis Area and Severity Index (PASI) score of 0 at all visits for 156 consecutive weeks (PASI = 0 group) with those that never achieve PASI = 0 (comparator group), using descriptive statistics and a multiple logistic regression model, published in the American Journal of Clinical Dermatology
- 26 Sep 2023 Results of post-hoc analysis evaluating the efficacy and safety of guselkumab in the Asian subpopulation of VOYAGE 1 and VOYAGE 2 through 5 years, published in the Dermatology and Therapy
- 15 Sep 2023 Results from VOYAGE-1 and -2 studies , evaluating guselkumab efficacy on regional psoriasis in a subset of psoriasis patients with a self-reported psoriatic arthritis (PsA) diagnosis, published in the Dermatology and Therapy